Neratinib (HKI-272) is a potent, irreversible pan-HER and MST1 inhibitor. It affects EGFR/HER2, PI3K/AKT, and MAPK signaling by irreversibly binding to HER kinases and blocking downstream pathways, effectively inhibiting cancer cell proliferation and inducing apoptosis.
Neratinib (HKI-272) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Neratinib (HKI-272) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.